Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative...
introduce the hypertension and dyslipidemia combination treatment 'Amosartan Q', under the local brand 'Lodarta' and in 2024 to introduce the combination hypertension treatment 'Amosartan Plus' under the local brand 'Bicartial-CTD'. Following these...
is a household name synonymous with healthy aging.” Niagen Bioscience recently reported its fourth quarter and full-year 2024 financial results, with strong full-year net sales at $99.6 million, up 19% from the prior year, and $44.7 million in cash...
Following this success, Medit introduced its best-selling i700 in 2021, i700 Wireless, and i600 in 2022, and i900 in 2024, providing a complete range of scanners for all types of dental practices. Medit is expanding its influence beyond intraoral...
a town in Poland to one of the greatest scientific centers in the United States," says Tomasz Nowakowski, winner of the 2024 Vilcek Prize for Creative Promise in Biomedical Science. "I am deeply grateful to [foundation founders] Jan and Marica...
Potent and Regular Potency). The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2024 financial year, the organization generated sales of €854 million and had over 3,000 employees. In 2022, CordenPharma was...
eligible uninsured patients through its Patient Assistance Program (PAP). IMKELDI, which received FDA approval in November 2024, is now available for order through specialty distribution partners in the U.S. IMKELDI’s advanced liquid formulation of...
States—prodisc C Vivo, prodisc C SK and prodisc C Nova. The prodisc C Nova product, released on a limited basis in October 2024, is the newest prodisc Cervical technology available in the U.S. Over 900 surgeons have used the Match-the-Disc system,...
symptom activity. Outcomes from the pivotal Phase 3 trial of Stanza were published in The Lancet in July 2024. This decision marks a significant step forward in increasing access to evidence-based, non-drug treatments for people with fibromyalgia,...
pan-European partnerships.” Mr. Omari will be based at Avanzanite’s second headquarters in Maastricht, the Netherlands. In 2024, Avanzanite continued its growth in the European orphan drug market, reaching over 120 patients across 12 countries and...
escalation cohorts with participants randomized to receive HB-500 or placebo. The first participant was dosed on July 1, 2024, and primary completion is expected in the second half of 2025. “HB-500 is designed to induce robust and durable immunity...
held earlier today. Mr. Doshi was nominated for election by the Board, together with nine returning directors, in December 2024. "Mr. Doshi is an extraordinary leader who brings significant experience in the biotechnology and pharmaceutical...
to improve anti-cancer therapy effectiveness and to meaningfully impact the quality of life for patients." In October 2024, Lutris successfully completed enrollment in the international phase 2 trial of LUT014 in patients with metastatic colorectal...
zebrafish embryos. Their study was published in the Journal of Hazardous Materials, made available online on 28 November, 2024. For this, the researchers used a methyl tert-butyl ether (MTBE)-based extraction strategy using a single biological...
$1 million financing between NLS and an accredited investor under a securities purchase agreement dated December 4, 2024, with the approval of certain items in NLS's extraordinary general meeting on January 7, 2025. As previously detailed in NLS's...
disease linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism. WCIRDC 2024 will return to a live, in-person meeting at the Hilton Universal City Hotel in Los Angeles, on December 12-14, 2024....
B-cell non-Hodgkin lymphoma (B-NHL) including Part 1 (dose escalation) and Part 2 (dose expansion). As of the November 20, 2024 cutoff date, a total of 29 B-NHL patients from Part 1 and Part 2 across all dose levels were treated and evaluated for...
industry trends and client needs, earning her recognition as a trusted advisor to both clients and colleagues. In 2024, Nicole joined Petauri to develop and lead the organization's US HEOR consultancy team. In this role, she is building the...
to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November 2024, this designation marks a crucial advancement in developing innovative therapies for patients facing these challenging...
and additional data at the upcoming Innovation in Obesity Therapeutics Summit in San Diego, CA, on December 11-12, 2024. Biolexis Co-founder Dr. David Bearss will present the latest data on BLX-7006's efficacy and its potential to provide a safe,...
